Compare Church & Dwight Co., Inc. (CHD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Church & Dwight Co., Inc. trades at $101.95 (market cap $24.38B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Church & Dwight Co., Inc. is far larger — about 310.4× Inovio Pharmaceuticals Inc's market cap, and Church & Dwight Co., Inc. pays a 1.2% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CHD | INO | |
|---|---|---|
Market Cap | $24.38B | $78.55M |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $2.87 |
52-Week Low | $81.60 | $0.66 |
Enterprise Value | $26.38B | $49.56M |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $103.30, up 0.06% today, near its consensus price target of $103.57. The stock shows bullish technical signals with strong moving averages, though oscillators indicate overbought conditions. Fundamentally, Q2 2026 earnings met estimates with 5.8% organic sales growth, and the company raised full-year guidance. Recent news highlights volume-driven performance and market share gains.
The outlook remains positive given raised earnings guidance and consistent dividend payments, but risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with 53% buy ratings, supporting a stable investment case for long-term growth in the consumer staples sector.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
